Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $30.0 million.

  • Aytu Biopharma's Cash & Equivalents rose 4719.58% to $30.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $30.0 million, marking a year-over-year increase of 4719.58%. This contributed to the annual value of $31.0 million for FY2025, which is 5471.36% up from last year.
  • Per Aytu Biopharma's latest filing, its Cash & Equivalents stood at $30.0 million for Q4 2025, which was up 4719.58% from $32.6 million recorded in Q3 2025.
  • Over the past 5 years, Aytu Biopharma's Cash & Equivalents peaked at $49.9 million during Q2 2021, and registered a low of $18.2 million during Q1 2025.
  • Its 5-year average for Cash & Equivalents is $26.8 million, with a median of $21.7 million in 2023.
  • In the last 5 years, Aytu Biopharma's Cash & Equivalents crashed by 6120.32% in 2022 and then skyrocketed by 6227.37% in 2025.
  • Over the past 5 years, Aytu Biopharma's Cash & Equivalents (Quarter) stood at $35.3 million in 2021, then crashed by 44.72% to $19.5 million in 2022, then grew by 0.14% to $19.5 million in 2023, then grew by 4.45% to $20.4 million in 2024, then skyrocketed by 47.2% to $30.0 million in 2025.
  • Its Cash & Equivalents stands at $30.0 million for Q4 2025, versus $32.6 million for Q3 2025 and $31.0 million for Q2 2025.